UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

May 11, 2020

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

May 06, 2020

Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.

April 23, 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

April 23, 2020

Nina Shah, MD, highlights some of the recent advances that have been made with CAR T-cell therapy in multiple myeloma, as well as other exciting updates in the space.

March 20, 2020

The need to establish preventive procedures that keep pace with the rapid evolution of coronavirus 2019 presents numerous challenges for the oncology field as institutions adapt standard treatment protocols to minimize the risk for virus spread among clinicians and patients alike.

March 11, 2020

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

February 18, 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses ongoing clinical trials in chronic lymphocytic leukemia (CLL).

February 13, 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.

February 08, 2020

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in follicular lymphoma.

February 07, 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential for daratumumab (Darzalex) maintenance therapy in multiple myeloma.

February 05, 2020

Rebecca L. Olin, MD, MSCE, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

February 01, 2020

Thomas Hope, MD, discusses considerations when making sequencing decisions for patients with gastroenteropancreatic neuroendocrine tumors.

February 01, 2020

Thomas Hope, MD, discusses treatment options for patients with gastroenteropancreatic neuroendocrine tumors.

January 29, 2020

Lawrence D. Kaplan, MD, discusses standard frontline treatment in follicular lymphoma, toxicities of some of the newer agents, and preliminary data with bispecific antibodies.

January 29, 2020

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

January 28, 2020

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

January 28, 2020

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

January 25, 2020

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

January 25, 2020

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

January 24, 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).